retatrutide phase 2 trial obesity nejm 2023 Another Promising Medication (Retatrutide) for retatrutide phase 2 trial obesity

What the Clinical Data Shows Updated on December 23, 2025 to include the FDA approval of the Wegovypill by Novo Nordisk

Reduced movement in the gut: GLP-1s can slow down the muscles that move food through your digestive system, contributing to bloating and trapped gas

Dose-Proportional Response Growth hormone release increases proportionally with dose without a corresponding spike in stress hormones giving clinicians a wider therapeutic window

In Asadi et al., meta-analysis study

For all drugs, except BSO, stock solutions were made in dimethyl sulfoxide (DMSO

Initial clinical findings suggest that GLP-1 receptor agonists could provide an effective therapeutic strategy in patients with AD and those at risk, however, there remains a lack of sufficient evidence in large clinical samples to draw any firm conclusions